- Home
- QUIK vs STTK Comparison
QUIK vs STTK Comparison
Compare QUIK & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QUIK
- STTK
- Stock Information
- Founded
- QUIK 1988
- STTK 2016
- Country
- QUIK United States
- STTK United States
- Employees
- QUIK N/A
- STTK N/A
- Industry
- QUIK Semiconductors
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- QUIK Technology
- STTK Health Care
- Exchange
- QUIK Nasdaq
- STTK Nasdaq
- Market Cap
- QUIK 100.1M
- STTK 83.8M
- IPO Year
- QUIK 1997
- STTK 2020
- Fundamental
- Price
- QUIK $5.62
- STTK $1.92
- Analyst Decision
- QUIK Strong Buy
- STTK Hold
- Analyst Count
- QUIK 3
- STTK 6
- Target Price
- QUIK $10.87
- STTK $2.67
- AVG Volume (30 Days)
- QUIK 179.8K
- STTK 1.6M
- Earning Date
- QUIK 11-10-2025
- STTK 11-13-2025
- Dividend Yield
- QUIK N/A
- STTK N/A
- EPS Growth
- QUIK N/A
- STTK N/A
- EPS
- QUIK N/A
- STTK N/A
- Revenue
- QUIK $18,359,000.00
- STTK $2,997,000.00
- Revenue This Year
- QUIK $11.58
- STTK N/A
- Revenue Next Year
- QUIK $22.73
- STTK N/A
- P/E Ratio
- QUIK N/A
- STTK N/A
- Revenue Growth
- QUIK N/A
- STTK N/A
- 52 Week Low
- QUIK $4.26
- STTK $0.69
- 52 Week High
- QUIK $13.36
- STTK $3.95
- Technical
- Relative Strength Index (RSI)
- QUIK 52.32
- STTK 72.13
- Support Level
- QUIK $5.00
- STTK $1.68
- Resistance Level
- QUIK $5.56
- STTK $2.04
- Average True Range (ATR)
- QUIK 0.24
- STTK 0.19
- MACD
- QUIK 0.06
- STTK 0.09
- Stochastic Oscillator
- QUIK 91.11
- STTK 89.29
About QUIK QuickLogic Corporation
QuickLogic Corp provides programmable silicon and software platforms to enable its customers to develop custom hardware products in a fast time-to-market and cost-effective way. QuickLogic is a fabless semiconductor company with a product range: embedded FPGA (eFPGA) intellectual property (IP), low power, multi-core semiconductor system-on-chips (SoCs), discrete FPGAs, and AI software. The full range of platforms, software tools, and eFPGA IP enables the practical and efficient adoption of AI, voice, and sensor processing across Aerospace, and Defense, Consumer/Industrial IoT, and Consumer Electronics markets.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.